X0609 4 2026-04-16 0002096997 Kailera Therapeutics, Inc. KLRA 0001752059 Kaplan Andrew T. false C/O BAIN CAPITAL INVESTORS LLC 200 CLARENDON STREET BOSTON MA 02116 true false true false false Common Stock 2026-04-20 4 C false 17857143 A 17857143 I See footnotes Common Stock 2026-04-20 4 P false 8398438 16.00 A 26255581 I See footnotes Series B Preferred Stock 2026-04-20 4 C false 17857143 0 D Common Stock 17857143 0 I See footnotes Stock Option (right to buy) 16.00 2026-04-16 4 A false 38300 0 A 2036-04-16 Common Stock 38300 38300 D Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to Mr. Kaplan's continued service through each such vesting date. Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus"). Mr. Kaplan is a Partner of Bain Capital Investors, LLC ("BCI"). BCI is the ultimate general partner of BCPE Perseus. As a result, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. Mr. Kaplan disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. /s/ Andrew Kaplan 2026-04-20